AU5957986A - Vector for the expression of gamma-interferon in mammal cells, method for its implementation, product obtained and pharmaceutical composition containing the gamma-interferon - Google Patents

Vector for the expression of gamma-interferon in mammal cells, method for its implementation, product obtained and pharmaceutical composition containing the gamma-interferon

Info

Publication number
AU5957986A
AU5957986A AU59579/86A AU5957986A AU5957986A AU 5957986 A AU5957986 A AU 5957986A AU 59579/86 A AU59579/86 A AU 59579/86A AU 5957986 A AU5957986 A AU 5957986A AU 5957986 A AU5957986 A AU 5957986A
Authority
AU
Australia
Prior art keywords
interferon
gamma
vector
expression
implementation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59579/86A
Inventor
Werner Altenburger
Therese Faure
Jean-Pierre Lecocq
Paul Sondermeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of AU5957986A publication Critical patent/AU5957986A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU59579/86A 1985-06-18 1986-06-16 Vector for the expression of gamma-interferon in mammal cells, method for its implementation, product obtained and pharmaceutical composition containing the gamma-interferon Abandoned AU5957986A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8509225 1985-06-18
FR8509225A FR2583429B1 (en) 1985-06-18 1985-06-18 INTERFERON U EXPRESSION VECTOR IN MAMMALIAN CELLS, PROCESS FOR IMPLEMENTING SAME AND PRODUCT OBTAINED, AND PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON U

Publications (1)

Publication Number Publication Date
AU5957986A true AU5957986A (en) 1987-01-13

Family

ID=9320362

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59579/86A Abandoned AU5957986A (en) 1985-06-18 1986-06-16 Vector for the expression of gamma-interferon in mammal cells, method for its implementation, product obtained and pharmaceutical composition containing the gamma-interferon

Country Status (7)

Country Link
EP (1) EP0206920A1 (en)
JP (1) JPS63500003A (en)
AU (1) AU5957986A (en)
DK (1) DK79887D0 (en)
FR (1) FR2583429B1 (en)
WO (1) WO1986007609A1 (en)
ZA (1) ZA864525B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
ZA875681B (en) * 1986-08-01 1988-04-27 Commw Scient Ind Res Org Recombinant vaccine
JPS6363381A (en) * 1986-09-04 1988-03-19 Kokuritsu Yobou Eisei Kenkyusho Recombinant vaccinia virus
FR2622456B1 (en) * 1987-10-29 1990-02-02 Transgene Sa RECOMBINANT FOWLPOX VIRUSES, HETEROLOGOUS PROTEIN EXPRESSION VECTORS AND POULTRY VACCINES DERIVED FROM THIS VIRUS
FR2632863B2 (en) * 1987-10-29 1990-08-31 Transgene Sa RECOMBINANT FOWLPOX VIRUS AND VACCINES DERIVED FROM SUCH VIRUSES
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
EP0469089B1 (en) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Generation of hybrid genes and proteins by virus-mediated recombination
GB8915870D0 (en) * 1989-07-11 1989-08-31 Nat Res Dev Dna coding for a polypeptide signal sequence in vaccinia virus
DE4002521A1 (en) * 1990-01-29 1991-08-01 Immuno Ag Recombinant plasmids for pox virus transformation - contg. multifunctional DNA sequence cassette to facilitate cloning of foreign DNA
FR2710536B1 (en) * 1993-09-29 1995-12-22 Transgene Sa Anti-cancer use of a viral vector comprising a gene which modulates the immune and / or inflammatory response.
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
CA2190290C (en) * 1994-05-13 2011-07-05 Michael J. Mastrangelo A method of inducing an immune response using vaccinia virus recombinants
FR2766091A1 (en) 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
EP2325321A1 (en) 1999-05-28 2011-05-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
PT1649023E (en) * 2003-07-21 2008-11-20 Transgene Sa Polypeptide having an improved cytosine deaminase activity
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI1006179A2 (en) 2009-01-13 2016-02-23 Transgène S A use of a mitochondrial nucleic acid fraction, adjuvant composition, vaccine composition, and part kit
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
JP5897464B2 (en) 2009-08-07 2016-03-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Composition for treating HBV infection
KR20130075732A (en) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 Influenza virus vaccines and uses thereof
AU2012312529B2 (en) 2011-09-20 2018-01-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
CN104870477B (en) 2012-10-23 2018-10-09 爱默蕾大学 GM-CSF and IL-4 conjugates, composition and relative method
WO2014099931A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CA3044074A1 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
CN114641306A (en) 2019-10-18 2022-06-17 免疫治疗有限公司 Improved LAMP constructs comprising cancer antigens
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
ZA831094B (en) * 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
AU570940B2 (en) * 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes

Also Published As

Publication number Publication date
DK79887A (en) 1987-02-17
FR2583429B1 (en) 1989-11-03
ZA864525B (en) 1987-03-25
DK79887D0 (en) 1987-02-17
JPS63500003A (en) 1988-01-07
FR2583429A1 (en) 1986-12-19
EP0206920A1 (en) 1986-12-30
WO1986007609A1 (en) 1986-12-31

Similar Documents

Publication Publication Date Title
AU5957986A (en) Vector for the expression of gamma-interferon in mammal cells, method for its implementation, product obtained and pharmaceutical composition containing the gamma-interferon
AU528641B2 (en) Pharmaceutical and dietary composition
AU579812B2 (en) Cell lines and their use for the production of proteins
AU590890B2 (en) Deep-draw-formed vessel and process for preparation thereof
DE2962568D1 (en) Antiinflammatory 4,5-diaryl-2-nitroimidazoles, method for their preparation and pharmaceutical composition containing them
JPS54135776A (en) Pharmaceutical composition and method
JPS5537198A (en) Enzyme derivative * production thereof and pharmaceutical composition containing same
IL79266A (en) Aralkylpiperidinylbenzyl alcohols,their preparation and pharmaceutical compositions containing them
AU544945B2 (en) Antigingirites composition of tranexamic acid and folic acid
AU1685288A (en) Cell culture of anchorage dependent cells, materials and products
AU601996B2 (en) Shampoo method and composition
PH20604A (en) Improvements in or relating to indanyl derivatives and pharmaceutical preparations containing them
AU581032B2 (en) Coloring material and process for preparation thereof
PT83301B (en) Expression of superoxide dismutase in eukaryotic cells and process for obtaining the same
AU576047B2 (en) Fibrinophilic urokinase complex and process for its preparation
DE3475071D1 (en) Silane-modified ester mixtures, process for their preparation and their use in pharmaceutical and cosmetic preparations
AU6872487A (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein
PT70046A (en) Thio-substituted diazacycloalkenes process for their preparation and pharmaceutical preparations
GB2160864B (en) 10-aryl-1, 8-dihydroxyanthrones and their esters, the process for preparation thereof and pharmaceutical and cosmetic compositions containing them
AU2456288A (en) Phthalazineacetic acid composition and tablet
ZA847975B (en) Beta-elemonic acid and pharmaceutical preparations
AU589450B2 (en) Novel Tetrahydroisoindolinones, process for their preparation and their use in plant protection
PH17058A (en) Dea-steroids,pharmaceutical preparations containing the same and method of use thereof
EP0196016A3 (en) 3-nitropyridine-derivatives, process for their preparation and pharmaceutical composition containing them
AU590211B2 (en) Improvements in compositions and methods for antisapstain treatment of timber and timber products